Benjamin J. Zeskind

CIK: 0001870062

Transaction Breakdown

Open Market Buys (P)4 (66.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

IMRX

Immuneering Corp

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

IMRX
Immuneering Corp
Jun 23, 2026
Purchase(P)
Direct
2.4K shares at avg. $4.56$11K
IMRX
Immuneering Corp
Feb 3, 2026
Award(A)
Stock Option
Direct
688K shares-
IMRX
Immuneering Corp
Jul 2, 2025
Purchase(P)
Direct
7K shares at avg. $3.53$25K
IMRX
Immuneering Corp
Jul 1, 2025
Purchase(P)
Direct
3K shares at avg. $3.38$10K
IMRX
Immuneering Corp
Jun 18, 2025
Purchase(P)
Direct
21K shares at avg. $2.39$50K
IMRX
Immuneering Corp
Feb 5, 2025
Award(A)
Stock Option
Direct
480K shares-

		Type	Shares	Price		Ownership
Jun 23, 2026	IMRX Immuneering Corp	Purchase(P)	2,400	$4.56	$10,948	Direct
Feb 3, 2026	IMRX Immuneering Corp	Award(A) Stock Option	688,000	-	-	Direct
Jul 2, 2025	IMRX Immuneering Corp	Purchase(P)	7,015	$3.53	$24,792	Direct
Jul 1, 2025	IMRX Immuneering Corp	Purchase(P)	2,985	$3.38	$10,087	Direct
Jun 18, 2025	IMRX Immuneering Corp	Purchase(P)	21,000	$2.39	$50,144	Direct
Feb 5, 2025	IMRX Immuneering Corp	Award(A) Stock Option	480,000	-	-	Direct

1-6 of 6 transactions

About Zeskind Benjamin J.

Zeskind Benjamin J. (SEC CIK 0001870062) files insider reports with the SEC as PRESIDENT AND CEO of Immuneering Corp (IMRX).

Signal8 holds 5 ownership filings by Zeskind Benjamin J., all Form 4s, filed between Feb 7, 2025 and Jun 24, 2026. Those filings report 6 transactions, from Feb 5, 2025 to Jun 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Zeskind Benjamin J.'s filings is in CAMBRIDGE, MA.

Recent filings by Zeskind Benjamin J.

Jun 23, 2026: Open-market purchase of IMRX shares (Form 4, code P).
Feb 3, 2026: Grant or award of IMRX derivative securities (Form 4, code A).
Jul 2, 2025: Open-market purchase of IMRX shares (Form 4, code P).
Jul 1, 2025: Open-market purchase of IMRX shares (Form 4, code P).
Jun 18, 2025: Open-market purchase of IMRX shares (Form 4, code P).

Other insiders filing for Immuneering Corp (IMRX)

Gengos Andrew, Chief Financial Officer
Hall Brett Matthew, CHIEF SCIENTIFIC OFFICER
Schall Thomas J., Director
HAUSMAN DIANA, Director
CARPENTER ROBERT J, Director
KEATING LAURIE, Director

How to read Form 4 transaction codes